A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Added to Chlorambucil Versus Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Trial Profile

A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Added to Chlorambucil Versus Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2018

At a glance

  • Drugs Ofatumumab (Primary) ; Chlorambucil
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPLEMENT 1
  • Sponsors Genmab; GlaxoSmithKline; Novartis Pharma A.G.; Novartis Pharmaceuticals
  • Most Recent Events

    • 12 Jul 2018 This trial has been discontinued in France.
    • 24 Apr 2018 Planned End Date changed from 1 Jul 2022 to 16 Jun 2022.
    • 15 Feb 2018 The study has been discontinued in Italy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top